EDT Cathie Wood’s ARK Investment buys 191.5K shares of 10x Genomics (TXG) todayStay Ahead of the Market: Discover outperforming stocks ...

Barclays analyst Luke Sergott lowered the firm’s price target on 10x Genomics (TXG) to $12 from $15 and keeps an Overweight rating on the ...

Charles Schwab Investment Management Inc. lessened its stake in 10x Genomics, Inc. (NASDAQ:TXG – Free Report) by 17.2% in the 4th quarter, according to the company in its most recent filing with the ...

CAMBRIDGE, Mass., April 03, 2025--(BUSINESS WIRE)--Vizgen, Inc., the life sciences company revolutionizing spatial genomics research and driving innovation in spatial multi-omics, today released ...

10x Genomics (NASDAQ:TXG – Get Free Report) last posted its quarterly earnings data on Wednesday, February 12th.The company reported ($0.40) earnings per share (EPS) for the quarter, missing the ...

As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the life sciences tools & ...

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell ...

Dear Customers, Researchers and Friends of Vizgen: On February 5th, we secured an important settlement putting an end to litigation, including cases in the U.S. and Europe, with 10X Genomics and ...

Founded in 2012, 10x Genomics (NASDAQ:TXG) is a biotech company developing gene-sequencing solutions based in the US. In a rather competitive market, TXG’s focus has been on single-cell and ...

What Happened? A number of stocks jumped in the afternoon session after markets rallied sharply on news that President Trump ...

10x Genomics and Syncell streamline cutting-edge analytics for life science research, while Nabla Bio is using generative AI to design completely new antibodies. Protagonist Therapeutics is ...